Virscio’s MD and/or PhD trained Study Directors and highly trained technical team engage with leading academic research institutions, venture-backed start-ups, and biotechnology and pharmaceutical companies around the world to advance a diversity of therapeutic discovery and development programs.
From early proof-of-concept safety and efficacy evaluations through good laboratory practice (GLP)-compliant, investigative new drug (IND)-enabling studies, we approach each Sponsor engagement with the commitment that the value creation process starts with developing a deep understanding of a Sponsor’s therapeutic strategy, existing preclinical data and clinical objectives. From that knowledge base, we engage in the study design and program planning process with two guiding principles:
As an institution we focus on creating value for the innovative Sponsors’ we serve, the investors that have supported them and the patients in need.
As scientists and clinicians we aim to design and execute the the most efficient preclinical programs possible – programs that will result in definitive, actionable data that has one of two outcomes:
Confirms the therapeutic hypothesis is clinically tenable, providing a clear follow on investment thesis and expedited path to clinic.
Disproves the therapeutic hypothesis, allowing for more efficient allocation of R&D resources to more promising programs.